Prevalence and factors associated with metabolic syndrome in an urban population of adults living with HIV in Nairobi, Kenya

Prevalence and factors associated with metabolic syndrome in an urban population of adults living with HIV in Nairobi, Kenya

Catherine Nduku Kiama^1,2,&, Joyce Njeri Wamicwe³, Elvis Omondi Oyugi², Mark Odhiambo Obonyo², Jane Githuku Mungai², Zeinab Gura Roka², Ann Mwangi¹

 

¹Moi University School of Public Health, Eldoret, Kenya, ²Field Epidemiology and Laboratory Training Program, Ministry of Health, Nairobi, Kenya, ³National AIDS and STI Control Program, Ministry of Health, Nairobi, Kenya

 

 

^&Corresponding author
Catherine Nduku Kiama, Field Epidemiology and Laboratory Training Program, Ministry of Health, Nairobi, Kenya

 

 

 

 

Metabolic syndrome is a cluster of risk factors in an individual that increase the risk of developing cardiovascular disease and Type 2 diabetes [1-3]. Patients with metabolic syndrome are more likely to suffer heart attack, stroke and cardiovascular mortality [4-7]. The global burden of cardiovascular disease and diabetes is increasing, with the biggest burden in lower and middle income countries. This is expected to rise substantially over the next two decades [8]. Human immunodeficiency virus (HIV) and use of antiretroviral treatment (ART) has led to an increase in cases of metabolic syndrome. HIV natural progression of disease is known to cause lipid abnormalities [9]. ART has resulted in improved quality of life, survival to older ages for those living with HIV and emergence of metabolic adverse events related to use of ART; dyslipidemia, changes in body composition, insulin resistance and glucose intolerance [10-12]. Prospective analysis of patients initiated on ART demonstrated 8.4% increase in prevalence of metabolic syndrome at 48 weeks of antiretroviral treatment [13]. It is estimated that 20-25% of adults globally have metabolic syndrome [14]. Prevalence in sub-Saharan Africa ranges from 0 -50% or higher and differs from population to population [15, 16]. Studies conducted in the general population from urban centres in Kenya reported the prevalence as 25.6% (several urban centres) and 34.6% (one urban centre) [17, 18]. Among people living with HIV (PLHIV), studies conducted in several African countries report prevalence of up to 60.6% [19-22]. According to the 2014 Kenya HIV Estimates Report, Kenya has 1.6 million PLHIV and 101,900 new HIV infections annually. There is limited data on metabolic syndrome in this population in Kenya since screening at the ART clinics is not conducted routinely. The burden of metabolic syndrome among PLHIV in Kenya is not well understood. We sought to find out the differences in socio-demographics and risk factors between the HIV-infected patients with metabolic syndrome and those without the syndrome. The aim of the study was to assess the prevalence and factors associated with metabolic syndrome in HIV-infected patients in a predominantly urban population in Nairobi, Kenya.

 

 

Study design and study population : this was a hospital based cross-sectional study. The study population was sampled HIV positive patients attending the Riruta Health centre ART clinic. The eligibility criteria for the study participants were; patients aged ≥18 years, visiting the ART clinic with a scheduled appointment for routine follow up, enrolled in care (either on prophylaxis or ART) at least 6 months prior to the study and fasted overnight (for 12 hours). We excluded clients with missing medical records, those on interrupted treatment, those visiting due to an acute illness and pregnant women. The Health centre serves as an outpatient facility offering HIV care and treatment amongst other services. It is situated in Dagoretti within the capital city of Nairobi and serves a predominantly urban population. It is considered a high volume HIV care and treatment site with an average of 100 HIV-infected patients scheduled for a clinic visit each day and a total of 3,027 patients active and on follow up at the start of the study. The study was conducted between May and June 2016.

 

Sample size calculation and selection of study participants: a sample size of 348 was estimated using Cochran's formula (1977) with the following assumptions; 34.6% prevalence of metabolic syndrome among the general population in Nairobi [7], 5% precision and a 95% confidence interval. The study participants were selected using random systematic sampling of HIV-infected patients attending routine clinic visits. The Health centre receives 100 HIV patients, on average, per day. We first allocated each patient a number from 1 to 100 and since we needed to enroll at least 20 patients per day, we selected every fifth patient to be included in the study until the required sample size was reached. With the help of the ART clinic staff, the selected patient was contacted on phone and advised to have supper as the last meal and skip breakfast on the clinic visit day in order to collect some blood for tests.

 

Operational definitions: metabolic syndrome was defined according to the harmonized Joint Scientific Statement criteria [23], which is the presence of any three of the five following risk factors; (1) waist circumference > 94cm for men or > 80cm for women, (2) triglycerides > 1.7 mmol/L or specific treatment for this abnormality, (3) HDL-Cholesterol < 1.03 mmol/L for men or < 1.29 mmol/L for women or specific treatment for this abnormality, (4) elevated blood pressure > 130/85 mmHg or treatment of previously diagnosed hypertension and (5) elevated fasting glucose > 5.6 mmol/L or treatment of previously diagnosed diabetes. Waist circumference was used to detect presence of abdominal obesity by measuring abdominal fat.

 

Data collection: the questionnaire was prepared in English. The clinician attending to the patient confirmed that the patient had supper as their last meal, obtained informed consent and administered the questionnaire. We collected socio-demographic and risk factor information through face to face interviews. The socio-demographic variables collected were; age, gender, highest level of education, marital status, religion, occupation and residence. Risk factor information collected were; family history (of hypertension, diabetes, asthma, cancers, cardiovascular disease), previous diagnosis (of diabetes, hypertension, lipid abnormalities), physical inactivity, fast food diet, stress, obesity, smoking and alcohol use. The clinician also carried out the physical examination and abstracted clinical information from the patients' files. Clinical information collected included; WHO staging of HIV disease, history of ART use, number of years on ART and last CD4 count. At the end of the visit, blood sugar testing was performed by the clinician at the point of care according to the Accu-Check glucometer manufacturer's specifications. About 4.5 mls of venous blood was collected from the patients at the facility laboratory by a trained phlebotomist, labelled with a unique number, age and sex and then shipped to the National Public Health Laboratory for lipid profile testing. Lipid profile testing was done using the Cobas C111 analyzer. At the end of each day, data was entered into Epi info v.7.14 (CDC TM) and stored in Microsoft Access database on a personal computer.

 

Data analysis: the data was analyzed using Epi info v.7.14 (CDC TM) software. Univariate analysis was performed and descriptive statistics reported using frequency distribution, proportions and means for socio-demographic and clinical variables. The prevalence of metabolic syndrome (95% Confidence Interval) was determined based on the definition criteria used in the study. Descriptive statistics were summarized for females and males to test if there was a statistical difference between the two groups. Bivariate analysis of risk factors undertaken using Odds Ratio as a measure of association and the statistical significance checked using Confidence Interval and Chi square test with P < 0.05 considered statistically significant. Binary logistic regression using the forward additive method was performed to identify the risk factors and to measure the variation in association between the independent and dependent variables. Factors with P < 0.25 from bivariate analysis were included in logistic regression to arrive at the final model of independent predictors of metabolic syndrome.

 

Ethical considerations: written informed consent was obtained from all the study participants. The study protocol was reviewed and approved by Moi Teaching and Referral Hospital Institutional Ethics and Research Committee (Approval No. 0001531).

 

 

A total of 360 patients were recruited with 66.9% being female (Table 1). Using the harmonized Joint Scientific Statement criteria, the overall prevalence of metabolic syndrome was 19.2% (95% C.I 15.3-23.7), higher in females than males. There was no case of metabolic syndrome observed among patients aged 18-24 years. The prevalence increased with age with patients older than 55 years having the highest prevalence (Figure 1). The prevalence of metabolic syndrome components in our study participants was; abdominal obesity 51.1%, low HDL-Cholesterol 32.5%, systolic hypertension 32.5%, hyperglycaemia 21.4% and hypertriglyceridemia 14.2%. The prevalence of abdominal obesity and low HDL-Cholesterol was higher among the female patients. However, the prevalence of hypertension, hyperglycaemia and hypertriglyceridemia was higher among the male patients (Table 2). There were either few or no patients aged 18-24 years with any of the metabolic syndrome components. On bivariate analysis, obesity (BMI > 30kg/m²), informal education, age ≥ 45 years and family history of hypertension were associated with increased odds of metabolic syndrome. Patients on antiretroviral treatment and those who were physically active had decreased odds of metabolic syndrome. Metabolic syndrome was not associated with gender, employment status, history of cardiovascular disease and diabetes in the family, smoking, alcohol use, consumption of fast foods and stress (Table 3). On multivariate analysis, there was a positive association between obesity, lack of formal education, family history of hypertension and occurrence of metabolic syndrome. Patients who were physically active had reduced odds of having metabolic syndrome (Table 4).

 

 

The study revealed that metabolic syndrome is prevalent among HIV-infected patients. The study prevalence is similar to that reported among HIV-infected patients using the same criteria in other countries; Australia (14%), Spain (16%), Barcelona (17%) and Ethiopia (21.1%) [13, 21, 24, 25]. The study prevalence was however much lower than the prevalence of metabolic syndrome in HIV-infected patients in Tanzania (25.6%), Denmark (27%), Cameroon (32.8%), Portugal (41.9%) and South Africa (60.6%) [19, 20, 22, 26, 27]. The study prevalence is also lower than the 34.6% and 25.6% prevalence reported among the general population living in urban centres in Kenya in 2012 and 2017 respectively [17, 18]. The presence of metabolic syndrome in HIV-infected patients puts them at an increased risk of developing cardiovascular disease and Type 2 diabetes [14, 15, 17]. This poses a higher risk of associated cardiovascular morbidity and mortality among HIV-infected patients in addition to opportunistic infections that they are predisposed to [24]. The study found that there were gender differences in prevalence of metabolic syndrome with a higher prevalence observed among female patients. Other studies have reported higher prevalence among females; 44.4 vs. 9.9% in Cameroon, and 25 vs. 12% in Australia [12, 17]. The observed higher prevalence among females in this population could be due to biological, hormonal and environmental factors that are thought to be contributing to occurrence of metabolic syndrome in women [1]. The prevalence was higher with increasing age and highest among those aged > 55 years. This observation has been reported in other similar studies conducted in Kenya, Tanzania, Ethiopia and Australia [18, 20, 21, 24]. The higher prevalence in older age-groups is supported by the fact that ageing has been shown to have a causal effect in metabolic syndrome [1]. Abdominal obesity, low HDL-cholesterol and hypertension were the most prevalent components in this urban population of HIV-infected persons. Abdominal obesity was present in over half while hypertension and low HDL-cholesterol in over one third of the study participants. Similarly, a study conducted among HIV-infected patients in Tanzania reported high prevalence of abdominal obesity (52.5%), low HDL-cholesterol (85.9%) and hypertension (49.2%) [20]. The high prevalence of these components suggests that there are many patients with precursors for metabolic syndrome. This presents an opportunity to delay development of cardiovascular disease and Type 2 diabetes if early cardiovascular risk assessment is offered with lifestyle modification for those identified to be at risk [1].

 

Abdominal obesity and low HDL-Cholesterol were more prevalent among the female patients while hypertriglyceridemia, hypertension and hyperglycaemia were more prevalent among the males. The prevalence of the individual components of metabolic syndrome by gender was consistent with figures reported in Tanzania and South Africa [20, 22]. Similarly, gender differences were also observed in an urban general population in Nairobi, Kenya [18]. The observed gender differences in the prevalence of the individual components in this population could be attributed to hormonal and biological factors [1]. Obesity, lack of formal education, ages > 55 years and family history of hypertension increased the likelihood of metabolic syndrome. Obesity is a known modifiable risk factor for metabolic syndrome [1, 28]. Having attained secondary or tertiary level education was found to be protective (OR = 0.3, P = 0.012) of metabolic syndrome in the general population in Kenya [18]. Ageing has been shown to have a causal effect in metabolic syndrome [1]. There was an increased likelihood of metabolic syndrome in older study participants drawn from the urban general population in Kenya [18]. Heredity and genetics have been shown to have a causal effect in metabolic syndrome [1]. The study also showed that physical activity and ART reduce likelihood of metabolic syndrome. Studies have shown that physical inactivity and a sedentary lifestyle predispose to metabolic syndrome [1, 29]. The finding on ART should be interpreted with caution since the number of patients not on ART (n = 5) in the study was small. A possible explanation for the small number of patients not on ART is that Kenya as a country has moved towards the test and treat approach where all HIV-infected patients are initiated on ART irrespective of the CD4 count. However, it is possible that the patients who were on ART in our study had received nutrition counselling and lifestyle modification advice during the health talks and psychosocial support group meetings at the treatment facility hence ART appears protective in this population. In contrast, other studies have demonstrated that ART leads to increased survival of HIV patients, improved quality of life and metabolic complications as adverse effects in patients receiving ART [22, 28, 30]. In another prospective cohort study, ART was shown to increase the prevalence of metabolic syndrome from 16.6% to 25% after 48 weeks of the study population receiving the treatment [13]. Our study had limitations. We could not establish causal association or the temporal sequence of events since this was a cross-sectional study. Fasting blood sugar and lipid profile testing was based on self-report of having fasted for 12 hours, there is possible misclassification of glycaemia and lipid profile abnormalities with potential to interpret random blood specimens as fasted states. However, this does not affect assessment of the prevalence of metabolic syndrome or factors associated with the syndrome among HIV-infected patients.

 

 

Metabolic syndrome is prevalent among HIV-infected persons. The high prevalence of abdominal obesity, dyslipidemia and hypertension suggests that there are many HIV-infected patients with precursors for metabolic syndrome. Obesity, lack of formal education, family history of hypertension, and physical inactivity are associated with metabolic syndrome. Screening for risk factors, promotion of healthy lifestyle, and nutrition counselling should be offered routinely in HIV care and treatment clinics.

 

 

The authors declare no competing interests.

 

 

Catherine Kiama participated in the study design, ethical approval, data collection, data analysis and manuscript writing. Joyce Wamicwe, Mark Obonyo, Elvis Oyugi and Jane Mungai contributed in revision of manuscript. Zeinab Gura and Ann Mwangi contributed towards the review of data and critical appraisal of manuscript. All authors read and approved the final draft of the manuscript.

 

 

This study was financially supported by the Field Epidemiology and Laboratory Training Program (FELTP-Kenya). I wish to express my sincere gratitude to the study participants, team of data collectors at Riruta Health centre, and the National Public Health Laboratory staff for processing the specimens.

 

 

Table 1: socio-demographic and clinical characteristics of adult HIV-infected patients, Riruta Health Centre, 2016

Table 2: prevalence of metabolic syndrome components among adult HIV-infected patients, Riruta Health Centre, 2016

Table 3: bivariate analysis of risk factors for metabolic syndrome in adult HIV-infected patients, Riruta Health Centre, 2016

Table 4: final logistic regression model of factors associated with metabolic syndrome among adult HIV-infected patients, Riruta Health Centre, 2016

Figure 1: prevalence of metabolic syndrome among adult HIV-infected patients by gender and age-group, Riruta Health Centre, 2016

 

 

1. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a consensus statement from the international diabetes federation. Diabet Med J Br Diabet Assoc. 2006 May; 23(5): 469-80. PubMed | Google Scholar


2. Alshehri AM. Metabolic syndrome and cardiovascular risk. J Fam Community Med. 2010 Aug; 17(2): 73. PubMed | Google Scholar


3. Fox CS. Cardiovascular disease risk factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends Cardiovasc Med. 2010 Apr; 20(3): 90. PubMed | Google Scholar


4. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in Nondiabetic European Men and Women. Arch Intern Med. 2004 May 24; 164(10): 1066-76. PubMed | Google Scholar


5. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr 1; 24(4): 683?9. PubMed | Google Scholar


6. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4; 288(21): 2709-16. PubMed | Google Scholar


7. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease. Diabetes Care. 2004 Nov 1; 27(11): 2676-81. PubMed | Google Scholar


8. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases: 2013-2020. Accessed on July 10 2017.


9. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992 May; 74(5): 1045-52. PubMed | Google Scholar


10. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS Lond Engl. 1998 May 7; 12(7): F51-58. PubMed | Google Scholar


11. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26; 338(13): 853-60. PubMed | Google Scholar


12. Ete T, Ranabir S, Thongam N, Ningthoujam B, Rajkumar N, Thongam B. Metabolic abnormalities in human immunodeficiency virus patients with protease inhibitor-based therapy. Indian J Sex Transm Dis. 2014; 35(2): 100-3. PubMed | Google Scholar


13. Palacios R, Santos J, González M, Ruiz J, Márquez M. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS. 2007 Mar 1; 18(3): 184-7. PubMed | Google Scholar


14. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. The Lancet. 2005 Sep; 366(9491): 1059-62. PubMed | Google Scholar


15. Isezuo SA, Ezunu E. Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. J Natl Med Assoc. 2005 Apr; 97(4): 557. PubMed | Google Scholar


16. Fezeu L, Balkau B, Kengne A-P, Sobngwi E, Mbanya JC. Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis. 2007 Jul; 193(1): 70. PubMed | Google Scholar


17. Omuse G, Maina D, Hoffman M, Mwangi J, Wambua C, Kagotho E et al. Metabolic syndrome and its predictors in an urban population in Kenya: a cross-sectional study. BMC Endocr Disord. 2017; 17: 37. Google Scholar


18. Kaduka LU, Kombe Y, Kenya E, Kuria E, Bore JK, Bukania ZN et al. Prevalence of metabolic syndrome among an urban population in Kenya. Diabetes Care. 2012 Apr; 35(4): 887-93. PubMed | Google Scholar


19. Dimodi HT, Etame LS, Nguimkeng BS, Mbappe FE, Ndoe NE, Tchinda JN et al. Prevalence of metabolic syndrome in HIV-infected Cameroonian Patients. World J AIDS. 2014; 4: 85-92. Google Scholar


20. Kagaruki G, Kimaro G, Mweya C, Kilale A, Mrisho R, Shao A et al. Prevalence and risk factors of metabolic syndrome among individuals living with HIV and receiving antiretroviral treatment in Tanzania. Br J Med Med Res. 2015 Jan 10; 5(10): 1317-27. Google Scholar


21. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J. 2012; 13: 43. PubMed | Google Scholar


22. Erasmus RT, Soita DJ, Hassan MS, Blanco-Blanco E, Vergotine Z, Kegne AP et al. High prevalence of diabetes mellitus and metabolic syndrome in a South African coloured population: baseline data of a study in Bellville, Cape Town. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2012 Oct 8;102(11 Pt 1): 841-4. PubMed | Google Scholar


23. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20; 120(16): 1640-5. PubMed | Google Scholar


24. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein and [corrected] hypoadiponectinemia. Diabetes Care. 2007 Jan; 30(1): 113-9. PubMed | Google Scholar


25. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics and related factors. Diabetes Care. 2005 Jan; 28(1): 132-7. PubMed | Google Scholar


26. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009 Jul 1; 10(6): 378-87. PubMed | Google Scholar


27. Santos A-C, Barros H. Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. Diab Vasc Dis Res. 2007 Dec 1; 4(4): 320-7. PubMed | Google Scholar


28. Paula AA, Falcão MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther. 2013 Dec 13; 10(1): 32. PubMed | Google Scholar


29. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program adult treatment panel III criteria for the metabolic syndrome. Diabetes. 2004 Aug; 53(8): 2087-94. PubMed | Google Scholar


30. Price J, Hoy J, Ridley E, Nyulasi I, Paul E, Woolley I. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health. 2015 Jun; 12(3): 240-8. PubMed | Google Scholar